Highest-materiality recent filing
Lexeo Therapeutics Q1 net loss $20.2M; cash $227.6M; LX2006 pivotal trial protocol submitted to FDA
Net loss $20.2M ($0.25/share) vs $32.7M ($0.99) in Q1 2025; R&D $15.7M, G&A $6.6M.
Lexeo appoints Dr. Laura Sepp-Lorenzino to board and Science & Technology Committee
Dr. Sepp-Lorenzino appointed April 28, 2026; term expires at 2028 annual meeting.
Net loss FY2025 $100.0M ($1.86/share) vs $98.3M ($3.09/share) in FY2024; Q4 loss $20.9M ($0.27).
LXEO Head of Research Dr. Adler departs; transition agreement through July 31, 2026
Dr. Adler stepped down as Head of Research effective February 1, 2026; will provide advisory services through July 31, 2026 or earlier termination.
Lexeo appoints COO and CMO; Eric Adler leaves to lead spin-off Myoventive
Jose Manuel Otero, former CTO, becomes COO effective Jan 2, 2026; base salary set at $510,000.
Lexeo Therapeutics reports positive interim Phase 1/2 clinical data for LX2020 in PKP2-ACM
LX2020 generally well tolerated in 10 participants; no clinically significant complement activation observed
Lexeo reports Q3 2025 net loss $20.3M; FDA open to accelerated BLA for LX2006; raised $154M equity
FDA agreed to consider pooling ongoing Phase I/II LX2006 data with pivotal trial data for BLA; co-primary endpoint earlier than 12 months okayed.
Lexeo prices $135M offering; FDA open to faster LX2006 approval path
Priced public offering of 15.625M shares at $8.00 and $10M private placement (pre-funded warrants) to Balyasny; gross proceeds ~$135M.
FDA open to pooling ongoing Phase 1/2 data with pivotal study to support BLA for accelerated approval.
Lexeo reports Q2 net loss $26.1M, advances LX2006 with Breakthrough Therapy, appoints new CFO
Net loss $26.1M ($0.60/sh) vs $21.2M ($0.64/sh) in Q2 2024; cash $152.5M expected to fund operations into 2028.
Lexeo stockholders elect two Class II directors, ratify KPMG as auditor
Steven Altschuler, M.D. elected with 19,800,126 votes for and 2,775,771 withheld (5,374,056 broker non-votes).
Lexeo raises $80M in private placement; cash runway into 2028
Gross proceeds ~$80M from sale of 20.79M shares and warrants at $2.8825/unit.
Lexeo Therapeutics reports Q1 net loss $32.7M, cash $106.9M; LX2006 data positive
Net loss of $32.7M ($0.99 per share) vs $21.7M ($0.77) in Q1 2024; R&D expense $17.2M, G&A $16.6M.
Lexeo reports positive interim Phase 1/2 data for LX2006 in FA cardiomyopathy; 25% LVMI reduction
Participants with abnormal LVMI at baseline achieved 25% mean reduction by 12 months or sooner.
Net loss $25.9M ($0.78/sh) for Q4 2024 vs $14.2M; FY net loss $98.3M ($3.09/sh) vs $66.4M.
Lexeo Therapeutics posts updated corporate presentation; no material new information in 8-K
Updated corporate presentation posted on website January 13, 2025, for investor and analyst meetings.
Lexeo Therapeutics appoints Dr. Kyle Rasbach as CFO effective Dec 18, 2024
Dr. Kyle Rasbach appointed CFO; CEO R. Nolan Townsend steps down as principal financial officer.
Lexeo reaches FDA alignment on accelerated approval for LX2006; Q3 net loss $29.5M, cash $157M
FDA agreed on co-primary registrational endpoints (LVMI reduction and frataxin expression) for LX2006 accelerated approval.
Lexeo announces positive interim Phase 1/2 data for LX1001 gene therapy in APOE4 Alzheimer's
LX1001 showed dose-dependent APOE2 expression in all participants with durability to 12 months.
Lexeo updates LX2020 cohort data timeline to late Q1/early Q2 2025; LX1001 data at CTAD Oct 2024
Expects to share Cohort 1 data from LX2020 for PKP2-ACM in late Q1 or early Q2 2025.
Lexeo Q2 net loss $21.2M; positive interim gene therapy data in FA cardiomyopathy
Net loss of $21.2M ($0.64 per share) vs $13.4M ($8.30) year ago; R&D $16.6M, G&A $7.0M.
Lexeo positive Phase 1/2 data for LX2006 in FA cardio: LVMI -11.4% at 12mo, safe
Mean LVMI reduction 11.4% at 12 months and 18.3% at 18 months in patients with elevated baseline LVMI.
Lexeo Therapeutics appoints Tim Van Hauwermeiren, argenx CEO, to Board
Appointment effective July 5, 2024; term expires at 2027 annual meeting.
Lexeo Therapeutics stockholders elect Class I director, ratify KPMG as auditor
Mette Kirstine Agger elected Class I director with 14,499,254 FOR, 7,450,057 WITHHELD, 1,249,160 broker non-votes.
Lexeo Q1 net loss $21.7M; cash $195.1M after $95M PIPE; pipeline milestones on track
Q1 2024 net loss $21.7M ($0.77/share) vs $18.7M ($11.58/share) in Q1 2023.
Director Bernard Davitian will not stand for reelection at Lexeo's 2024 annual meeting
Bernard Davitian notified Lexeo on April 16, 2024, that he will not seek reelection.
Lexeo Therapeutics licenses full data and IP for LX2006 FA cardiomyopathy gene therapy from Cornell
Upfront fees total $600,000; potential regulatory milestones up to $2.1M and commercial milestones up to $100M.
Lexeo Therapeutics receives FDA Fast Track designation for LX2006 gene therapy for FA cardiomyopathy
FDA granted Fast Track designation for LX2006 (AAVrh.10hFXN gene therapy) for Friedreich's ataxia cardiomyopathy.
On April 28, 2026 (the “ Appointment Date ”), Dr. Laura Sepp-Lorenzino was appointed to the board of directors (the “ Board ”) of Lexeo Therapeutics, Inc.
On November 11, 2024 (the “ Appointment Date ”), Tolga Tanguler was appointed to the board of directors of the Company (the “ Board ”).
On July 5, 2024 (the “Appointment Date”), Tim Van Hauwermeiren was appointed to the board of directors (the “Board”) of Lexeo Therapeutics, Inc. (the “Company”).
On April 16, 2024, Bernard Davitian notified Lexeo Therapeutics, Inc. (the “Company”) that he does not intend to stand for reelection at the Company’s 2024 annual meeting of stockholders on June 25, 2024.
Max materiality 0.85 · Median 0.62 · Most common event other_material